Pharma channel feed

Gener­ic Adder­all short­ages con­tin­ue as sev­er­al man­u­fac­tur­ers stare down sup­ply squeezes

3 years ago
Manufacturing

Klick scoops up Google health­care chief for new lead­ing role

3 years ago
Marketing

As No­vo Nordisk be­gins PhII sick­le cell tri­al, it snags a lat­er-stage blood dis­or­der drug in $1.1B For­ma buy

3 years ago
Deals

Up­dat­ed: As­traZeneca wins last-minute in­junc­tion to tem­porar­i­ly stop for­mer ex­ec from start­ing GSK job

3 years ago
People

Once val­ued at more than $5B, Intar­cia Ther­a­peu­tics sees all of its ex­ecs de­part and its fi­nal shot at FDA de­nied

3 years ago
FDA+

An­nu­al brand plan­ning un­der­way, but it’s about time for a dis­rup­tion, says for­mer Big Phar­ma com­mer­cial leader

3 years ago
Marketing

Cur­rax dou­bles down on ‘pi­o­neer’ weight-loss med Con­trave in new­ly en­er­gized obe­si­ty drug mar­ket

3 years ago
Marketing

Sanofi's Paul Hud­son scores an FDA OK for a rare dis­ease drug — af­ter a lengthy R&D odyssey

3 years ago
FDA+

ICER reaf­firms Qsymia as most cost-ef­fec­tive obe­si­ty treat­ment in fi­nal re­port

3 years ago

A $280M life sci­ence fa­cil­i­ty is com­ing to Col­orado as it gains more in­ter­est from biotech de­vel­op­ers

3 years ago
R&D

No­var­tis' En­tresto in­fringes on uni­ver­si­ty patents, law­suit claims

3 years ago
Law

Am­gen posts terse up­date on PhI­II Lumakras win — but just how big?

3 years ago
R&D

Flori­da sues FDA over drag­ging its feet on Cana­di­an drug im­port pro­gram's ap­proval

3 years ago
FDA+

Cor­rect­ed: FDA al­lows Curis to restart en­rolling pa­tients in leukemia tri­al as shares tum­ble 9%

3 years ago
FDA+

Genen­tech opens new $250M bi­o­log­ics man­u­fac­tur­ing site in South San Fran­cis­co

3 years ago
Manufacturing

Medtron­ic taps for­mer Dis­ney star Jen­nifer Stone to pro­mote in­sulin pen

3 years ago
Marketing

Pfiz­er picks up first chief mar­ket­ing of­fi­cer from big tech Al­pha­bet’s Ver­i­ly

3 years ago
People
Marketing

Phar­ma's day in court: Is the dai­ly down­pour of law­suits giv­ing phar­ma com­pa­nies a bad rep?

3 years ago
Marketing

Mar­ket­ingRx roundup: J&J cy­clists hit the road for an­nu­al can­cer re­search ride; Gilead, Pfiz­er top pa­tient view in Asia

3 years ago
Marketing

Il­lu­mi­na taps ten­nis star Chris Evert for its first ge­nomics fo­rum along­side Barack Oba­ma and Bill Gates

3 years ago
People
Marketing

Dig­i­tal re­call? On­col­o­gists see dozens of on­line ads every month but on­ly re­mem­ber a hand­ful — study

3 years ago
Marketing

HHS lines up near­ly $700M in sup­ply deals to com­bat mon­key­pox and stock up on a small­pox treat­ment

3 years ago
Manufacturing

#ESC22: Bay­er's chron­ic kid­ney dis­ease drug miss­es the mark on low­er­ing car­dio­vas­cu­lar death

3 years ago
R&D

#ESC22: BMS-J&J’s mil­vex­i­an miss­es com­pos­ite end­point, but duo to push drug for­ward with signs of sec­ondary stroke pre­ven­tion and ‘flat bleed­ing curve’

3 years ago
R&D
First page Previous page 176177178179180181182 Next page Last page
A service from the Financial Times